Novel Regimens in COVID-19 Treatment

Tanta University

Status and phase: Enrolling; Phase 3

Conditions: Corona Virus Infection; COVID

Treatments: Drug: Nitazoxanide

Study type: Interventional

Funder types: Other

Identifiers

NCT04382846

tanta covid treatment

Details and patient eligibility

About

Nitazoxanide has been shown to have a clinical efficacy against severe acute respiratory syndrome coronavirus 2; ivermectin has also demonstrated a remarkable experimental efficacy with a potential to be used for Coronavirus disease 2019.

Full description

Nitazoxanide has been shown to have a clinical efficacy against severe acute respiratory syndrome coronavirus; ivermectin has also demonstrated a remarkable experimental efficacy with a potential to be used for Coronavirus disease 2019. Some studies demonstrated the efficacy of combined regimen of nitazoxanide and azithromycin or ivermectin and chloroquine.

Enrollment: 160 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with COVID-19 infection

Exclusion criteria

• Allergy or contraindication to the drugs.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

160 participants in 2 patient groups

Nitazoxanide

Experimental group

Description:

Nitazoxanide with standard protocol of treatment

Treatment:

Drug: Nitazoxanide

Control group

No Intervention group

Description:

Standard protocol alone